We employed a small molecular inhibitor of JAK2 kinase, CHZ868, and the data showed that CHZ868 decreased the accumulation of LC3B-II and inhibited the degradation of SQSTM1 in CRC cells following IL-6 treatment (Fig. 2a). The gene discussed is SQSTM1; the disease is colorectal carcinoma.